Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Fernandes, T. Gatheral, R. Dhunnookchand, D. Bilton, R. Wilson, M. Loebinger (London, United Kingdom). Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis. Eur Respir J 2014; 44: Suppl. 58, 4686

Member's Comments

No comment yet.

Related content which might interest you: Pseudomonas aeruginosa pneumonia in the community Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Bacterial colonization in patients with bronchiectasis Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Should pseudomonas aeruginosa be the main target in bronchiectasis? Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Pulmonary infections with pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 642s Year: 2004 Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 Frequency of multidrug resistant pathogens in healthcare associated pneumonia Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Pseudomonas aeruginosa colonisation in patients without bronchiectasis Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 COPD and pseudomonas aeruginosa, an association Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 Nicotinamide and bacterial killing in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014